Trehalose-6,6'-dibehenate

Cat. No.: HY-112137 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Trehalose-6,6'-dibehenate is a bioactive glycolipid that can be used to prepare vaccine adjuvant.

For research use only. We do not sell to patients.

Trehalose-6,6'-dibehenate Chemical Structure

CAS No. : 66758-35-8

Size	Price	Stock	Quantity
5 mg	USD 360	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Trehalose-6,6'-dibehenate is a bioactive glycolipid that can be used to prepare vaccine adjuvant^[1].

Molecular Weight

987.43

Formula

C₅₆H₁₀₆O₁₃

CAS No.

66758-35-8

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCCCCCCCCCC(OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@@H]1O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)COC(CCCCCCCCCCCCCCCCCCCCC)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMF : 0.5 mg/mL (0.51 mM; ultrasonic and warming and heat to 60°C)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/1% Tween-80 in Saline water
Solubility: 4.95 mg/mL (5.01 mM); Suspended solution; Need ultrasonic

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 2.5 mg/mL (2.53 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (263 KB) SDS (393 KB)

COA (241 KB) HNMR (305 KB) MS (85 KB)

Handling Instructions (2659 KB)

References

[1]. Yu H, et, al. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infect Immun. 2010 May;78(5):2272-82. [Content Brief]